EPHA2 and lung cancer: We have recently shown that EphA2 is overexpressed in lung cancer and harbors a gain-of-function point mutation in some squamous cell carcinomas, and EphA2 inhibition in addition to rapamycin exposure in lung cancer cells reduced their proliferation in vitro[9].